Skip to main content
Journal cover image

Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis

Conferences
Briganti, A; Luz, M; Yu, E; Pieczonka, C; Murphy, D; Armstrong, AJ; Hellmis, E; Kretz, T; Spiegelhalder, P; Adorjan, P; Ghadessi, M; Suzuki, H ...
Published in: EUROPEAN UROLOGY
March 2025

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

EUROPEAN UROLOGY

EISSN

1873-7560

ISSN

0302-2838

Publication Date

March 2025

Volume

87

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Briganti, A., Luz, M., Yu, E., Pieczonka, C., Murphy, D., Armstrong, A. J., … Suzuki, H. (2025). Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. In EUROPEAN UROLOGY (Vol. 87).
Briganti, A., M. Luz, E. Yu, C. Pieczonka, D. Murphy, A. J. Armstrong, E. Hellmis, et al. “Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis.” In EUROPEAN UROLOGY, Vol. 87, 2025.
Briganti A, Luz M, Yu E, Pieczonka C, Murphy D, Armstrong AJ, Hellmis E, Kretz T, Spiegelhalder P, Adorjan P, Ghadessi M, Verholen F, Suzuki H. Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. EUROPEAN UROLOGY. 2025.
Journal cover image

Published In

EUROPEAN UROLOGY

EISSN

1873-7560

ISSN

0302-2838

Publication Date

March 2025

Volume

87

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences